Icrucumab ( IMC-18F1) is a humanized IgG1 monoclonal antibody targeting vascular endothelial growth factor receptor-1.Icrucumab has antitumor activity.Icrucumab has been studied in metastatic colon cancer.
CAS Number:
[1024603-92-6]
Target:
LY 3012212 , IMC-18F1
* VAT and and shipping costs not included. Errors and price changes excepted